LENZ Therapeutics, Inc. · NASDAQ:LENZ
LENZ Therapeutics — Investor Presentation (March 2024)
22 slides from LENZ Therapeutics's investor presentation, March 2024
Slide 1: Company Presentation
Company Presentation March 2024 NASDAQ: LENZ
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are
Slide 3: Positioned for leadership in $3B+ Presbyopia market
Positioned for leadership in $3B+ Presbyopia market Late stage exclusive aceclidine-based eye drop with potential of providing all day seamless vision for the vast majority of presbyopes Unique MOA Only miotic shown to achieve pupil sweet spot <2mm w/o myopic shift Profile Best-in-Class Phase 2 perf
Slide 4: Presbyopia, the inevitable loss of near vision
Problem Presbyopia, the inevitable loss of near vision Research shows adults over 50 lose on average 1.5 lines of near vision per 6 years1 Impacts ~128M2 People in the US Impacts over Potential $3B+ Market 120M People in the US 4 1. Progression of Near Vision Loss and Incidence of Near Vision Impair
Slide 5: Promise of a once-daily eye drop solution is welcomed by all presbyopes
Promise of a once-daily eye drop solution is welcomed by all presbyopes Adapting Early Busy Midlife Active Aging Seriously Consider Seriously Consider Seriously Consider 68% 62% 51% 4 – 7 days/wk Usage* 4 – 7 days/wk Usage* 4 – 7 days/wk Usage* 80% 79% 79% 45 – 54 55 – 64 +65 N=452 N=448 N=458 5 LEN
Slide 6: How the eye focuses light for near and distance vision
How the eye focuses light for near and distance vision in the healthy eye, and the problem of presbyopia Distance vision Near vision for healthy eyes Near vision in Presbyopia The lens is in its native shape which The lens changes shape, known as The lens hardens with age, limiting enables far visio
Slide 7: Ideal presbyopia eye drop creates a pinhole pupil while avoiding a myopic shift
Ideal presbyopia eye drop creates a pinhole pupil while avoiding a myopic shift that impacts distance vision Create a pinhole pupil While avoiding a myopic shift FDA requires 3 lines of near vision improvement while not losing 1 or more lines of distance vision 7
Slide 8: Pupil diameter correlates to depth of focus and near vision improvement
Pupil diameter correlates to depth of focus and near vision improvement Total Depth-of-Focus Near Vision Improvement 2 Total Depth-of-Focus (D) 6 0.6 Lighting Conditions (cd/m2) Lines Improvement 20 (Dark) 5 0.5 1.5 200 (Office) 4 2000 (Cloudy Day) 0.4 Average 1 3 0.3 2 0.2 0.5 1 0.1 0 1 2 3 4 5 6 1
Slide 9: Aceclidine is the only pupil selective miotic
Aceclidine is the only pupil selective miotic Iris sphincter muscle Ciliary muscle Independence ratio EC50 (nmol/l) EC50 (nmol/l) ciliary to iris EC50 25,000 Longitudinal 28 Aceclidine 900 20,000 Circular 22 1,800 3,360 Longitudinal 1.9 Pilocarpine 2,840 Circular 1.6 Carbachol 106 574 Longitudinal 5
Slide 10: Uniquely achieving <2mm pupil without myopic shift
Uniquely achieving <2mm pupil without myopic shift Iris sphincter stimulation Corresponding ciliary stimulation -0.17 Diopters myopia 2% Aceclidine 1.40 mm 0.078 mm lens shift 0.07 mm increase lens thickness -1.3 Diopters myopia 2% Pilocarpine 1.35 mm 0.234 mm lens shift 0.2 mm increase lens thickne
Slide 11: One diopter of myopic shift is meaningful
One diopter of myopic shift is meaningful 20/20 20/50 Perfect vision 1 Diopter myopic shift 20/40 20/40 Drivers test line 11
Slide 12: Addressable market is largest when pinhole effect is decoupled from myopic shift
Addressable market is largest when pinhole effect is decoupled from myopic shift Adapting Early Busy Midlife Active Aging Presbyopia market segments 40 – 54 yrs 55 – 64 yrs Over 65 yrs 31% 30% 39% Target Market Aceclidine 100% “All Eyes / All Day” Other <20% Early Presbyopes / Emmetropes miotics 12
Slide 13: Aceclidine Preservative free eye drop
Aceclidine Preservative free eye drop The first and only, pupil selective miotic with potential to meet needs of all presbyopes and provide best-in-class potential for near vision improvement Best-in-class potential agent for presbyopia with ability to address broad patient population 13
Slide 14: Phase 2 INSIGHT trial compared LNZ100 and LNZ101 against vehicle
Phase 2 INSIGHT trial compared LNZ100 and LNZ101 against vehicle on key variables LNZ100 Study Design • Multicenter safety and effectiveness study 1.75% Aceclidine • 5 US Sites, 50+ Patients - Ready to use • Double-masked, randomized, crossover - Preservative Free Eye Drop • Placebo controlled • 10
Slide 15: Pupil diameter within the sweet spot for hours
Pupil diameter within the sweet spot for 10 hours Mean Pupil Size Near Vision Improvement Biomarker LNZ100 (n=49) LNZ101 (n=50) Vehicle (n=51) 4.0 Average pupil size reduced to 3.5 ~1.6mm at 30 minutes Pupil size (mm) 3.0 Pupil size correlates to lines of near vision improvement 2.5 2.04 2.0 Average
Slide 16: Primary endpoint met: ≥3-line improvement in near vision over time
Primary 1 hour endpoint met and 10 hours duration ≥3-Line improvement in BCDVA at near over time (No loss of 5 or more letters distance) LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) Extended category leadership with potential best-in-class data for efficacy and duration for both LNZ100 and LNZ101 Part
Slide 17: Secondary endpoint met: ≥2-line improvement in near vision over time
Secondary 1 hour endpoint met, 10 hours duration ≥2-Line improvement in BCDVA at near over time (No loss of 5 or more letters distance) LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) 92 92 Both LNZ100 and LNZ101 86 86 provided clinically meaningful 2 82 78 78 78 lines or more NV improvement Participants
Slide 18: No impact to distance vision in normal and low light
No impact to distance vision in normal and low light Distance Best-Corrected Distance Visual Acuity LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) No impact to distance vision in normal light 20/15 BETTER DISTANCE VISION Logmar No impact to distance vision in low light Well tolerated, No drug related se
Slide 19: CLARITY Phase 3 study design based on INSIGHT
CLARITY 1 and 2 study design based on INSIGHT Phase 2 Randomized, double masked, vehicle-controlled, Phase 3 studies (NCT05656027 & NCT05728944) Refractive range Inclusive of post-refractive Baseline near visual Ages 45 - 75 between -4 to +1 surgery and/or pseudophakic acuity 20/50 or worse CLARITY
Slide 20: European historical use of 400M doses confirms expected low side effect profile
European historical use of 400M doses confirms expected low side effect profile Long history of use for Glaucoma • Approved for Glaucoma in Europe in 1970’s • Approved at higher concentration and QID dosing • Marketed in 12 European countries and 400M doses • Rapid anterior chamber penetration • Wel
Slide 21: Management and Board
Management and Board Management: Eef Schimmelpennink Dan Chevallard Shawn Olsson Marc Odrich, MD Marv Garrett Melissa Rosness President and CEO Chief Financial Officer Chief Commercial Officer Chief Medical Officer SVP Regulatory & Quality VP CMC & Manufacturing Board: Jeff George, Zach Scheiner, Ph
Slide 22: Medical Advisors
Medical Advisors Ophthalmology: Steven Dell, MD Deepinder John Doane, MD Kathryn Hatch, MD Terry Kim, MD Colman Kraff, MD Robert Osher, MD Medical Director Dell Dhaliwal, MD Discover Vision Centers Mass. Eye & Ear. Asst. Prof. Prof. of Ophthalmology Kraff Eye Institute Cincinnati Eye Institute Laser
LENZ Therapeutics — Investor Presentation (March 2024) on 6ix